Literature DB >> 2177633

Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of calcyclin: tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells.

X J Guo1, A F Chambers, C L Parfett, P Waterhouse, L C Murphy, R E Reid, A M Craig, D R Edwards, D T Denhardt.   

Abstract

A mouse mRNA, provisionally designated 5B10, has been cloned based on its inducibility by serum in quiescent murine fibroblasts. Here we report the full-length complementary DNA sequence and a partial characterization. There are about five copies of the gene in the mouse genome. Sequence analysis of the 5B10 coding region reveals 94 and 97% amino acid identity to human and rat calcyclin, respectively. Although the coding region has been highly conserved during evolution of the rodent and human genomes, the untranslated flanking sequences differ significantly. A protein of Mr about 8000 was produced by in vitro translation of the mRNA transcribed in vitro from 5B10 complementary DNA in a riboprobe vector. An antiserum raised against a portion of the predicted human calcyclin protein cross-reacted with this mouse protein. 5B10 mRNA was found in greatest amount in organs containing proliferating cells, e.g., epidermis, skin, stomach, uterus of pregnant mouse, placenta, and decidua. Brain, liver, mature thymus, and skeletal muscle had little or no detectable 5B10 mRNA. 5B10 mRNA levels were higher in cells treated with 7,12-dimethylbenzanthracene and 12-O-tetradecanoylphorbol-13-acetate than in their normal counterparts, suggesting a role in tumorigenesis. In addition, high 5B10 mRNA levels were associated with metastatic ability in a series of ras-transformed cells, in proportion to levels of ras p21 expressed by the cells, implicating 5B10 even more deeply in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177633

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  8 in total

1.  Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment.

Authors:  S W Lee; C Tomasetto; K Swisshelm; K Keyomarsi; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  1H NMR assignments of apo calcyclin and comparative structural analysis with calbindin D9k and S100 beta.

Authors:  B C Potts; G Carlström; K Okazaki; H Hidaka; W J Chazin
Journal:  Protein Sci       Date:  1996-11       Impact factor: 6.725

3.  Evolution of EF-hand calcium-modulated proteins. III. Exon sequences confirm most dendrograms based on protein sequences: calmodulin dendrograms show significant lack of parallelism.

Authors:  S Nakayama; R H Kretsinger
Journal:  J Mol Evol       Date:  1993-05       Impact factor: 2.395

4.  Increased proteinase expression during tumor progression of cell lines down-modulated for TIMP levels: a new transformation paradigm? [corrected].

Authors:  R Khokha; P Waterhouse; P Lala; M Zimmer; D T Denhardt; R Khokka
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 5.  S100A6 protein: functional roles.

Authors:  Rosario Donato; Guglielmo Sorci; Ileana Giambanco
Journal:  Cell Mol Life Sci       Date:  2017-04-17       Impact factor: 9.261

6.  Positive selection of candidate tumor-suppressor genes by subtractive hybridization.

Authors:  S W Lee; C Tomasetto; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 7.  Joining S100 proteins and migration: for better or for worse, in sickness and in health.

Authors:  Stephane R Gross; Connie Goh Then Sin; Roger Barraclough; Philip S Rudland
Journal:  Cell Mol Life Sci       Date:  2013-06-30       Impact factor: 9.261

8.  Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma.

Authors:  K Komatsu; Y Kobune-Fujiwara; A Andoh; S Ishiguro; H Hunai; N Suzuki; M Kameyama; K Murata; J Miyoshi; H Akedo; M Tatsuta; H Nakamura
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.